Canaccord Genuity Reiterates a 'Hold' on Protalix BioTherapeutics (PLX); Modest U.S. But Strong In Israel

June 25, 2012 8:34 AM EDT Send to a Friend
Get Alerts PLX Hot Sheet
Price: $4.15 --0%

Rating Summary:
    3 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade PLX Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Hold' on Protalix BioTherapeutics (NYSE: PLX) price target of $6.00 (from $8.00).

Analyst, Ritu Baral, said, "We see modest US but robust Israel & ROW sales potential; EU delayed to 2016. We think PLX/partner Pfizer's (NYSE: PFE) Elelyso (taliglucerase) may ultimately get ~15% of the $1.2B+ worldwide Gaucher's market. We are lowering our target to $6 due to later-than-expected ROW sales. Our target is based on a DCF of projected US/ROW sales and pNPV of future EU sales."

For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.

Shares of Protalix BioTherapeutics closed at $6.19 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment